Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 19/20 | 0.54 |
| ▸ | MAPK13 | O15264 | 11/20 | 0.54 |
| ▸ | MAPK12 | P53778 | 11/20 | 0.54 |
| ▸ | MAPK11 | Q15759 | 11/20 | 0.54 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.54 |
| ▸ | RAF1 | P04049 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6786364 | 1.00 | MAPK14 (0.54) | MAPK14MAPK13MAPK12MAPK11MAPK9 | |
| SCHEMBL6612844 | 1.00 | MAPK14 (0.54) | MAPK14MAPK13MAPK12MAPK11MAPK9 | |
| SCHEMBL6612848 | 1.00 | MAPK14 (0.54) | MAPK14MAPK13MAPK12MAPK11MAPK9 | |
| SCHEMBL6784602 | 0.85 | MAPK14 (0.60) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL6784607 | 0.85 | MAPK14 (0.60) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL6615969 | 0.85 | MAPK14 (0.60) | MAPK14MAPK13MAPK12MAPK11MAPK9 | |
| SCHEMBL6615964 | 0.85 | MAPK14 (0.60) | MAPK14MAPK13MAPK12MAPK11MAPK9 | |
| SCHEMBL7991937 | 0.76 | MAPK14 (0.67) | MAPK14MAPK13MAPK12MAPK11MAPK9 | |
| SCHEMBL7979995 | 0.75 | MAPK14 (0.68) | MAPK14MAPK13MAPK12MAPK11MAPK9 | |
| SCHEMBL6784449 | 0.74 | MAPK14 (0.45) | MAPK14MAPK13MAPK12MAPK11MAPK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030100558-A1 | Triazole compounds useful in treating diseases associated with unwanted cytokine activity | PROCTER & GAMBLE COMPANY, THE | 2003-05-29 | — | — | US | claimed |
| US-6787555-B2 | SUCH AS 4-(4-FLUOROPHENYL)-5-(2-PHENYLMETHYLAMINO)PYRIMIDIN-4-YL)-1-ETHOXYMETHYL -(1,2,3)TRIAZOLE FOR INHIBITION OF RELEASE OF INFLAMMATORY INTERLEUKINS; FOR TREATMENT OF OSTEOARTHRITIS, RHEUMATOID ARTHRITIS, AND CONGESTIVE HEART FAILURE | THE PROCTER & GAMBLE COMPANY | 2004-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100558-A1 | Triazole compounds useful in treating diseases associated with unwanted cytokine activity | IL4, IL1A, IL2 | MAPK14 3429/4885MAPK13 4097/4885MAPK12 4447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.